Subnanomolar MAS-related G protein-coupled receptor-X2/B2 antagonists with efficacy in human mast cells and disease models

2025 · Ghazl Hamwi, Mohamad Alnouri, Sven Verdonck, Piotr Leonczak, Shaswati Chaki, Stefan Frischbutter, Pavel Kolkhir, Michaela Matthey, Constantin Kopp, Marek Bednarski, Yvonne Riedel, Daniel Marx, Sophie Clemens, Vigneshwaran Namasivayam, Susanne Gattner, Dominik Thimm, Katharina Sylvester, Katharina Wolf, Andreas Kremer, Steven De Jonghe, Daniela Wenzel, Magdalena Kotańska, Hydar Ali, Piet Herdewijn, Christa Müller · Signal Transduction and Targeted Therapy

Abstract

Abstract The MAS-related G protein-coupled receptor-X2 (MRGPRX2), an orphan receptor expressed on mast cells (MCs), is upregulated upon inflammation and induces hypersensitivity and inflammatory diseases. In contrast to the large number of MRGPRX2 agonists, only a few antagonists have been described, and no optimization has been reported to improve potency, selectivity, and drug-like properties. Antagonists with ancillary inhibition of the putative mouse ortholog MRGPRB2 have not been described. Here, we present a multi-disciplinary approach involving chemistry, biology, and computational science, resulting in the development of a small-molecule MRGPRX2 antagonist (PSB-172656, 3-ethyl-7,8-difluoro-2-isopropylbenzo[4,5]imidazo [1,2-a] pyrimidin-4(1H)-one) based on a fragment screening hit. The compound exhibits metabolic stability, low cytotoxicity, and competitive blockade of MRGPRX2 activation induced by a diverse range of agonists. It displays subnanomolar potency in Ca2+ mobilization assays (K i value 0.142 nM) and was found to block MRGPRX2-mediated Gαq and Gαi1 dissociation, in addition to β-arrestin-2 recruitment. PSB-172656 is selective for MRGPRX2 versus all other MRGPRX subtypes. Its effect on MCs was confirmed in cell lines, including rat basophilic leukemia cells (RBL-2H3) recombinantly expressing human MRGPRX2, human Laboratory of Allergic Diseases 2 (LAD2) MCs, and native human skin MCs. PSB-172656 was found to additionally block the putative mouse ortholog of MRGPRX2, MRGPRB2, as determined in Ca2+ mobilization assays (K i 0.302 nM), and to prevent mouse tracheal contractions, local allergic reactions, and systemic anaphylactic symptoms. PSB-172656 constitutes a unique pharmacological tool and has the potential to be developed as a drug for mast cell-mediated hypersensitivity reactions and chronic inflammatory diseases, addressing a huge unmet medical need.

ADInstruments products used

Publication Details

Journal
Signal Transduction and Targeted Therapy
Volume
10
Issue
1
Publisher
Springer Science and Business Media LLC
ISSN
2059-3635